Acquisition leverage Since Stryker acquired Arrinex in 2019, there is a clear path to scale the ClariFix cryoablation platform through Stryker’s global sales, service, and distribution networks, potentially accelerating adoption in hospitals and ambulatory centers.

FDA clearance moat ClariFix is FDA-cleared for adults with chronic rhinitis and is positioned as the first and only device in this category, providing a strong competitive edge for ENTs and payer discussions, with room to expand indications as evidence grows.

ENT market focus The minimally invasive, durable solution directly targets ENT clinics and chronic rhinitis treatment settings, presenting sales opportunities with high-value payer discussions and potential bundled service offerings.

Portfolio expansion Opportunities exist to broaden the product family with additional cryoablation accessories or related ENT tools, leveraging Stryker’s platform to create integrated treatment workflows for chronic rhinitis.

Global expansion With a Silicon Valley base and mid-sized team, ARRINEX/Stryker can pursue international growth leveraging regulatory, clinical, and distribution capabilities to broaden access beyond the US.